MS8709

Cat. No.:	HY-162362
Molecular Formula:	$C_{64}H_{95}F_2N_{11}O_7S$
Molecular Weight:	1200.57
Target:	GLP Receptor; PROTACs
Pathway:	GPCR/G Protein; PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	MS8709 (10), a potential anticancer therapeutic, is a first-in-class G9a/GLP PROTAC degrader. MS8709 (10) is based on G9a/GLP inhibitor UNC0642 and recruits the von Hippel Lindau (VHL) E3 ligase (Red: G9a/GLP inhibitor UNC0642; Blue: VHL ligand; Black: linker)[1].
In Vitro	MS8709 (10) induces significant degradation of G9a and GLP at both 0.3 and 3 μM. Most notably, compound 10 (with an 11-carbon linker) induced more than 70% of G9a and around 50% of GLP degradation at 0.3 μM and complete degradation for both proteins at 3 μM[1]. MS8709 (10, 1 μM, 24 h) induces G9a/GLP degradation in a VHL- and UPS-dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Julia Velez, et al. Discovery of the First-in-class G9a/GLP PROTAC Degrader. BioRxiv. Posted February 29, 2024.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA